Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 ( 177 Lu‐J591) for metastatic castration‐resistant prostate cancer

[ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

(2018) Michael S Hofman et al.   LANCET ONCOLOGY

Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group

(2018) Andrea K. Miyahira et al.   PROSTATE

Phase I trial of fractionated-dose 177lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC).

(2017) S. T. Tagawa et al.   JOURNAL OF CLINICAL ONCOLOGY

Radioimmunotherapy-based conditioning for hematopoietic stem cell transplantation: Another step forward

(2016) Alaa M. Ali et al.   BLOOD REVIEWS

(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted  -Particle Radiopharmaceutical Therapy

(2016) A. P. Kiess et al.   JOURNAL OF NUCLEAR MEDICINE

German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

(2016) Kambiz Rahbar et al.   JOURNAL OF NUCLEAR MEDICINE

A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer

(2015) N. Pandit-Taskar et al.   CLINICAL CANCER RESEARCH

Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy

(2015) B. Meller et al.   EJNMMI Research

Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

(2013) S. T. Tagawa et al.   CLINICAL CANCER RESEARCH

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

(2013) C. Parker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer

(2013) Scott T. Tagawa et al.   Frontiers in Oncology

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen

(2011) M. J. Evans et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-prostate-Specific membrane antigen-based radioimmunotherapy for prostate cancer

(2010) Scott T. Tagawa et al.   CANCER

Randomized Trial Comparing Conventional-Dose With High-Dose Conformal Radiation Therapy in Early-Stage Adenocarcinoma of the Prostate: Long-Term Results From Proton Radiation Oncology Group/American College of Radiology 95-09

(2010) Anthony L. Zietman et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer

(2007) Deborah A. Kuban et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS